FIELD: biotechnology.
SUBSTANCE: described is a method for preparing a personalized vaccine against a malignant tumour. Method comprises inputting amino acid information for a set of candidate peptide sequences using a computer processor into a trained machine-trained model for predicting presentation of HLA class II peptides to obtain a plurality of presentation predictions, selecting, based on at least a plurality of presentation predictions, a subgroup of peptide sequences from a set of candidate peptide sequences to obtain a set of selected peptide sequences and preparing a personalized cancer vaccine.
EFFECT: invention extends the range of methods for preparing a pharmaceutical composition using a trained machine-trained model.
19 cl, 46 dwg, 18 tbl, 15 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IDENTIFICATION, PRODUCTION AND USE OF NEOANTIGENS | 2016 |
|
RU2729116C2 |
| NEOANTIGEN VECTORS BASED ON ALPHAVIRUS | 2018 |
|
RU2803566C2 |
| GENETICALLY MODIFIED MICE EXPRESSING CHIMERIC MOLECULES OF THE MAJOR HISTOCOMPATIBILITY COMPLEX | 2012 |
|
RU2797549C2 |
| MILK MIXTURE WITH SPECIFIC PEPTIDES OF BETA-LACTOGLOBULIN | 2019 |
|
RU2780747C2 |
| GENETICALLY MODIFIED MICE EXPRESSING CHIMERIC MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULES | 2012 |
|
RU2660564C2 |
| METHODS OF PREDICTING THE APPLICABILITY OF DISEASE-SPECIFIC AMINO ACID MODIFICATIONS FOR IMMUNOTHERAPY | 2018 |
|
RU2799341C2 |
| RA ANTIGEN PEPTIDES | 2004 |
|
RU2359974C2 |
| METHODS FOR TREATMENT OF AUTOIMMUNE DISEASE USING ALLOGENIC T-CELLS | 2017 |
|
RU2773831C2 |
| PREVENTIVE OR THERAPEUTIC POLYEPITOPIC ANTI-TUBERCULOSIS VACCINE CONSTRUCTION PROVIDING INDUCTION OF CELLULAR IMMUNE RESPONSE OF CD4+ OR CD8+ T-LYMPHOCYTES | 2011 |
|
RU2539035C2 |
| Bcl-2 PROTEINS, FRAGMENTS THEREOF, AND APPLICATION THEREOF IN PATIENTS WITH MALIGNANT TUMOUR | 2004 |
|
RU2367468C2 |
